Orbus Therapeutics

10 articles about Orbus Therapeutics

• Orbus Therapeutics Announces First Patient Enrolled in Phase 1 Clinical Study in Newly Diagnosed Glioblastoma

  9/6/2023

  Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, announced today that the first patient has been enrolled in its Phase 1b study combining temozolomide and eflornithine in patients newly diagnosed with glioblastoma.

• Orbus Therapeutics Enters Exclusive License Agreement for Intellectual Property Related to Treatment of Rare Pediatric Syndrome with Eflornithine

  1/10/2023

  Orbus Therapeutics Inc. announced an exclusive license agreement with Michigan State University (MSU) and Helen DeVos Children’s Hospital (HDVCH), part of Corewell Health ® (formerly Spectrum Health), that grants Orbus exclusive rights to intellectual property related to the method of use of eflornithine in the treatment of a novel pediatric condition known as Bachmann-Bupp Syndrome (BABS).

• Orbus Therapeutics’ Phase 3 Eflornithine STELLAR Study Reaches Full Patient Enrollment

  1/19/2022

  Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, today announced that patient enrollment of its Phase 3 STELLAR clinical study of eflornithine in patients with recurrent anaplastic astrocytoma is complete.

• Orbus Therapeutics Announces Positive Outcome of Pre-Planned Interim Futility Analysis for Phase 3 Eflornithine STELLAR Study

  3/2/2021

  Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, today announced a positive outcome of the pre-planned interim analysis for futility in its Phase 3 STELLAR clinical study of eflornithine in patients

• Orbus Therapeutics Receives U.S. Patent for Eflornithine Formulations- Patent relates to a solution of eflornithine for oral administration currently being evaluated in Orbus’ Phase 3 STELLAR study in rare brain cancer -

  12/23/2020

  Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, announced that it has been granted patent No. 10,786,470 entitled “Formulations for Administration of Eflornithine,” by the United States Patent and Trademark Office (USPTO). The patent, which was granted on September 29, 2020, covers a solution of eflornithine hydrochloride hydrat

• 

  Biopharma Money on the Move: October 21-27

  10/28/2020

  Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.

• Orbus Therapeutics Expands Series A Financing to $71 Million to Support Ongoing STELLAR Phase 3 Study in Rare Brain CancerProceeds to fund STELLAR study and additional clinical studies in patients with malignant gliomas

  10/22/2020

  Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, today announced that that it has closed an expansion of its Series A financing. As part of this expanded financing, Abingworth LLP has joined the existing Series A investors led by Longitude Capital, H.I.G. BioVentures and Adams Street Partners. In conjunction with the financing, Kur

• Orbus Therapeutics Announces ASCO Study Design Presentation Of Pivotal Clinical Trial In Patients With Late-Stage Brain Cancer

  6/5/2017

• Orbus Therapeutics Selects DSG, Inc. For EDC And IWRS In Recurrent Anaplastic Astrocytoma Clinical Study

  9/30/2016

• Orbus Therapeutics Announces Enrollment Of First Patient In Phase 3 Trial In Late-Stage Brain Cancer

  9/26/2016